Item 5.07 Submission of Matters to a Vote of Security Holders.



On June 22, 2021, Kindred Biosciences, Inc. ("KindredBio") held its Annual
Meeting of Stockholders (the "2021 Annual Meeting"). As of the record date of
the 2021 Annual Meeting, there were 45,273,504 shares of KindredBio's common
stock issued and outstanding. At the 2021 Annual Meeting, 35,864,203 shares of
common stock were present in person or represented by proxy. At the 2021 Annual
Meeting, KindredBio's stockholders voted on the three proposals set forth below,
each of which is described in detail in the 2021 Proxy Statement. The number of
votes for and against each proposal and the number of abstentions and broker
non-votes with respect to each proposal are set forth below.

1.  KindredBio's stockholders elected Raymond Townsend, Pharm.D. and Ervin
Veszprémi as Class II directors to serve until the 2024 annual meeting of
stockholders and until their respective successors are duly elected and
qualified.
                                Votes For              Votes Against              Abstentions              Broker Non-Votes
Raymond Townsend,              18,502,080                11,420,497                 200,213                   5,741,413
Pharm.D.
Ervin Veszprémi                15,989,773                13,931,035                 201,982                   5,741,413

2. KindredBio's stockholders approved the proposal to approve, on an advisory basis, the compensation of KindredBio's named executive officers.


 Votes For     Votes Against    Abstentions     Broker Non-Votes
 28,962,834      1,080,353         79,603          5,741,413

3. KindredBio's stockholders approved the proposal to ratify the appointment of KMJ Corbin & Company LLP as KindredBio's independent registered public accounting firm for the fiscal year ending December 31, 2021.


 Votes For     Votes Against    Abstentions     Broker Non-Votes
 35,655,776       195,103          13,324              0



Important Information for Investors and Stockholders
This communication does not constitute a solicitation of any vote or approval in
connection with the proposed acquisition of KindredBio by Elanco Animal Health
Incorporated ("Elanco" and such proposed acquisition, the "Merger"). KindredBio
intends to file with the SEC and mail to its stockholders a definitive proxy
statement in connection with the proposed Merger. BEFORE MAKING ANY VOTING
DECISION, KINDREDBIO'S STOCKHOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR
ENTIRETY THE PROXY STATEMENT (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO)
AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED WITH THE SEC WHEN THEY BECOME
AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT KINDREDBIO AND
THE PROPOSED MERGER. The proposals for the Merger will be made solely through
the proxy statement. Investors and stockholders may obtain copies of the proxy
statement and other documents filed with the SEC by KindredBio (when they became
available) free of charge from the SEC's website at www.sec.gov or by accessing
KindredBio's website at www.kindredbio.com. In addition, a copy of the proxy
statement (when it becomes available) may be obtained free of charge from
Investor Relations at Kindred Biosciences, Inc., 1555 Bayshore Highway, Suite
200, Burlingame, CA 94010. Copies of the documents filed with the SEC by Elanco
(when they become available) may be obtained free of charge from the SEC's
website at www.sec.gov or by accessing Elanco's website at www.elanco.com.

Participants in the Merger Solicitation

--------------------------------------------------------------------------------



Elanco, KindredBio, and certain of their directors, executive officers and
employees may be considered participants in the solicitation of proxies from
KindredBio's stockholders with respect to the proposed transactions. Information
regarding the persons who may, under the SEC rules, be deemed participants in
the solicitation of KindredBio's stockholders in connection with the proposed
Merger and a description of their direct and indirect interests therein, by
security holdings or otherwise, will be set forth in the definitive proxy
statement that KindredBio intends to file with the SEC when it becomes
available. Information about Elanco's directors and executive officers is set
forth in Elanco's definitive proxy statement for its 2021 Annual Meeting of
Shareholders, which was filed with the SEC on March 25, 2021. Information about
KindredBio's directors and executive officers is set forth in KindredBio's
definitive proxy statement for its 2021 Annual Meeting of Stockholders, which
was filed with the SEC on April 29, 2021. These documents may be obtained as
indicated above.

Cautionary Statement Regarding Forward-Looking Statements



Statements included in this communication that are not a description of
historical facts are forward-looking statements. Words or phrases such as
"believe," "may," "could," "will," "estimate," "continue," "anticipate,"
"intend," "seek," "plan," "expect," "should," "would" or similar expressions are
intended to identify forward-looking statements, and are based on our current
beliefs and expectations. These forward-looking statements include, without
limitation, statements regarding the proposed acquisition of KindredBio, the
expected timetable for completing the transaction, future financial and
operating results, benefits and synergies of the transaction, future
opportunities for the combined businesses and any other statements regarding
events or developments that Elanco believes or anticipates will or may occur in
the future. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. There are a
number of important factors that could cause actual events to differ materially
from those suggested or indicated by such forward-looking statements. These
factors include risks and uncertainties related to, among other things:
uncertainties as to the timing of the Merger; the possibility that competing
acquisition proposals will be made; the inability to complete the Merger due to
the failure to obtain KindredBio's stockholder adoption of the Merger Agreement
or the failure to satisfy other conditions to completion of the Merger,
including required regulatory approvals; the failure of the transaction to close
for any other reason; the effects of disruption caused by the transaction making
it more difficult to maintain relationships with employees, collaborators,
customers, vendors and other business partners; the risk that stockholder
litigation in connection with the Merger may result in significant costs of
defense, indemnification and liability; diversion of management's attention from
ongoing business concerns and other risks and uncertainties that may affect
future results of the combined company, including the risks described in the
section entitled "Risk Factors" in Elanco's and KindredBio's Annual Reports on
Form 10-K for the year ended December 31, 2020 and Quarterly Reports on Form
10-Q for the quarter ended March 31, 2021. All forward-looking statements are
qualified in their entirety by this cautionary statement and neither Elanco nor
KindredBio undertake any obligation to revise or update this communication to
reflect events or circumstances after the date hereof, except as required by
law.


Item 9.01  Financial Statements and Exhibits.

Exhibit No.                 Description
        104                 Cover Page Interactive Data File (embedded within the Inline XBRL
                            document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses